I sat down with Dr. Yasir Elamin to get his thoughts on his presentation at ASCO regarding patient reported outcomes and health-related quality of life with Taletrectinib in advanced ROS1 non-small cell lung cancer (NSCLC) from the TRUST-II Study.
I sat down with Professor Sanjay Popat to get his thoughts on the ROSETTA Lung-02 abstract presented at ASCO and what it could mean for clinical practice, future research, and patient care.